UPDATE 1-Bristol's Opdivo cuts risk of lung cancer death for some

Chicago May 29 (Reuters) - Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested...